Prognostic Impact of Cardiorenal Anemia Syndrome in Patients With Atrial Functional Mitral Regurgitation ― Subanalysis From REVEAL-AFMR Registry ―
Background: Atrial functional mitral regurgitation (AFMR) frequently affects older patients, but the high-risk patient subgroups requiring careful follow-up and targeted therapy remain unclear. AFMR causes venous congestion and reduced forward cardiac output, which may accelerate chronic kidney disease (CKD) and anemia. Cardiorenal anemia syndrome (CRAS) is a known prognostic factor in heart failure (HF), and AFMR-specific hemodynamic disturbances may amplify its consequences. The aim of this study was to evaluate the impact of CRAS on cardiovascular outcomes in AFMR.
Authors
- Madoka Sano
- Kojiro Morita (ORCID: https://orcid.org/0000-0002-2306-0669)
- Taiji Okada (ORCID: https://orcid.org/0000-0002-8878-3446)
- Y Sato
- K Sato
- Y Abe
- on behalf of the REVEAL-AFMR Study Group
- Yohei Ohno
- Nobuyuki Kagiyama
- Yutaka Furukawa
- Masaru Obokata
- Tomoko Machino-Ohtsuka
- Tomohiro Kaneko
- Masashi Amano
Institutions
- Tokai University (JP)
- University of Tsukuba (JP)
- St. Marianna University School of Medicine (JP)
- Gunma University (JP)
- Shimane University (JP)
- Juntendo University (JP)
- Osaka City General Hospital (JP)
- National Cerebral and Cardiovascular Center (JP)
- Kobe City Medical Center General Hospital (JP)
- The University of Tokyo (JP)
Publication Details
- Journal
- Circulation Reports
- Published
- 2026-06-08
- DOI
- https://doi.org/10.1253/circrep.cr-26-0045
- Primary Topic
- Cardiovascular Function and Risk Factors
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eli Lilly and Company
- AstraZeneca
- Japan Agency for Medical Research and Development
- Boehringer Ingelheim Japan
- Nippon Shinyaku
- Fukuda Foundation for Medical Technology
- Japanese Circulation Society
- Mochida Memorial Foundation for Medical and Pharmaceutical Research
- Otsuka Pharmaceutical
- Japan Society for the Promotion of Science
- Daiichi Sankyo Europe